Porcine circovirus type 2 VLP vaccine
AssigneeMeiji Animal Health Co., Ltd.
InventorsTakeshi Arakawa, Yukihiro Tamaki, Kenichi Yamazaki, Jinya Yamada, Nozomi Taira, Hirotaka Uefuji, Ikuko Yonamine, Tetsuya Harakuni, Rui Yamaguchi
Life of this patent
Estimating the term…
Abstract
Provided is PCV2 VLP that can be used as a vaccine for use in the field of animal husbandry and that has high molecular stability against physicochemical load. A fusion protein according to the present invention includes a capsid protein of porcine circovirus type 2 and an immunoglobulin-binding domain.
Claims8
A fusion protein comprising a capsid protein of porcine circovirus type 2 and an immunoglobulin-binding domain, wherein the immunoglobulin-binding domain has a structure (i) or (ii) below:
- (i) a structure in which a B1 domain and a B2 domain of protein G are linked;
- and
- (ii) a structure in which two of a Z domain of protein A are linked, and
- wherein the fusion protein is capable of forming a virus like particle (VLP) after a heat treatment at 97° C. for 30 minutes.
A method for producing a fusion protein comprising a capsid protein of porcine circovirus type 2 and an immunoglobulin-binding domain, the method comprising the steps of:
- preparing an expression vector containing a nucleic acid which encodes the fusion protein comprising the capsid protein of the porcine circovirus type 2 and the immunoglobulin binding domain;
- and
- introducing the expression vector into Escherichia coli to express the fusion protein,
- wherein the immunoglobulin-binding domain has a structure (i) or (ii) below:
- (i) a structure in which a B1 domain and a B2 domain of protein G are linked;
- and
- ii) a structure in which two of a Z domain of protein A are linked, and
- wherein the fusion protein is capable of forming a VLP after a heat treatment at 97° C. for 30 minutes.
Dependencies are inferred from the claim text.